NASDAQ
06.06.25 | 17:04
3,990 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Inozyme Pharma kündigt Vorstandsboni im Rahmen von Fusionsplänen an | 1 | Investing.com Deutsch | ||
| Mo | Inozyme Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.05. | Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More | 68 | Zacks | ||
| 19.05. | BioMarin agrees to acquire Inozyme for $270m | 4 | Pharmaceutical Technology | ||
| INOZYME PHARMA Aktie jetzt für 0€ handeln | |||||
| 18.05. | BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition | 4 | Insider Monkey | ||
| 16.05. | TD Cowen cuts Inozyme stock rating post-acquisition news | 3 | Investing.com | ||
| 16.05. | BioMarin's $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease | 2 | MedCity News | ||
| 16.05. | BioMarin stock rises following Inozyme Pharma acquisition | 2 | Investing.com | ||
| 16.05. | BioMarin-Aktie steigt nach Übernahme von Inozyme Pharma | 5 | Investing.com Deutsch | ||
| 16.05. | Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 | 2 | Investing.com | ||
| 16.05. | BioMarin stock holds $105 target, acquires INZY for $270M | 1 | Investing.com | ||
| 16.05. | BioMarin to buy rare disease drugmaker Inozyme for $270M | 2 | BioPharma Dive | ||
| 16.05. | BioMarin stock rises on strategic INZY acquisition | 1 | Investing.com | ||
| 16.05. | BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover | 4 | Investor's Business Daily | ||
| 16.05. | BioMarin to Acquire Inozyme Pharma for $270M | 2 | Contract Pharma | ||
| 16.05. | BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era | 3 | FierceBiotech | ||
| 16.05. | BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash | 436 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in... ► Artikel lesen | |
| 16.05. | BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal | 3 | Seeking Alpha | ||
| 16.05. | BioMarin to acquire Inozyme for $270 million | 1 | Investing.com | ||
| 16.05. | BioMarin übernimmt Inozyme für 270 Millionen US-Dollar | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 32,800 | 0,00 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
| QIAGEN | 40,135 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| NOVAVAX | 6,416 | +4,80 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| STRYKER | 340,20 | +1,58 % | Former Intuitive, Stryker VP joins Think Surgical as EVP to advance surgical robot tech | ||
| ILLUMINA | 73,51 | +2,20 % | Does Illumina (ILMN) Have Good Long-Term Growth Prospects? | ||
| CRISPR THERAPEUTICS | 36,000 | +6,51 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
| AAP IMPLANTATE | 1,400 | +5,26 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
| OCUGEN | 0,927 | +11,13 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,468 | +7,99 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,188 | +8,68 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,660 | +5,77 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
| DEFENCE THERAPEUTICS | 0,526 | +6,05 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,610 | +0,15 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
| KUROS BIOSCIENCES | 26,300 | -0,08 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen |
Das Unternehmen INOZYME PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INOZYME PHARMA INC finden Sie auf Wallstreet Online.